LRRK2 and Parkinson disease: Therapeutically, it remains challenging to predict if one drug targeting a specific pathway in a rare genetic type of PD (e.g., LRRK2-G2019S) will also stop the pathology in other pathways and across the broad spectrum of PD patients.